The FDA approved the PARP inhibitor rucaparib to treat women with advanced 
ovarian cancer who have already been treated with at least two chemotherapies 
and have a BRCA1 or BRCA2 gene mutation identified by an approved companion 
diagnostic test. The agency also gave a nod to the FoundationFocus CDxBRCA test 
to detect BRCA alterations.